“To truly understand a new drug’s effect on movement disorders, sponsors need objective, real-world data that can only be captured by a medical-grade precision motion device and combined with traditional clinical endpoints for a complete view on efficacy,” James Corrigan, President, and CEO of ERT
PHILADELPHIA (PRWEB) June 10, 2020
ERT, the global leader in clinical endpoints data collection, today announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement.
Current clinical trial assessments in movement disorders such as Parkinson’s disease (PD), Multiple Sclerosis (MS), and Ataxia are subjective and based on episodic visits. Consequently, drug development decisions in Central Nervous System (CNS) and other pathologies result in large-scale trials that are costly and highly unpredictable. APDM’s wearable platform is designed to address these challenges by providing precision motion data collected with medical-grade wearable sensors and novel digital endpoints to guide critical decision-making and allow for more objective, efficient, and effective evaluation of therapies.
“We are thrilled that our advanced wearable platform will be added to ERT’s suite of proven eClinical technologies to help innovative clinical trial sponsors minimize uncertainty and risk in the development of CNS and movement disorder treatments, ultimately improving patients’ lives,” said Dr. Mateo Aboy, Co-Founder & Chairman of APDM.
As an example, by integrating high-quality Patient Reported Outcomes (PRO) data captured by ERT’s industry-leading eCOA platform with data from APDM’s wearables and digital endpoints, trial sponsors gain robust insights and more comprehensive safety and efficacy data as they develop new medical treatments for many therapies including movement-related disorders. The integrated solution can be used to support in-clinic assessments as well as in trials conducted virtually.
“To truly understand a new drug’s effect on movement disorders, sponsors need objective, real-world data that can only be captured by a medical-grade precision motion device and combined with traditional clinical endpoints for a complete view on efficacy,” said James Corrigan, President, and CEO of ERT. “APDM’s advanced technology and broad understanding of objective precision movement measurement complements ERT’s expertise in high-quality clinical trial data collection, delivering the most efficient and effective approach for trial sponsors developing new medical treatments for the millions of patients living with movement disorders today.”
Visit ert.com/wearables-and-digital-biomarkers for more information on ERT’s Wearables and Digital Biomarkers. Financial terms of the transaction were not disclosed.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.
APDM was founded with the objective of creating novel technologies to 1) enable the scientific community to conduct quality research in movement science, 2) accelerate and reduce risk in clinical trials by introducing a new generation of validated endpoints, and 3) improve the quality of life of people with movement disorders through precision medicine.
APDM commercializes Opal Wearable Sensors, Mobility Lab, and Mobility Exchange. It serves the academic (biomarker and digital endpoint discovery) and pharma/biotech (clinical trials) markets with best-in-class wearable and digital biomarker solutions.
For more information, go to apdm.com.